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Bacterial biofilms are of concern in medicine due to natural drug resistance. Many 
bacterial species that infect humans including Escherichia coli, Staphylococcus 
aureus, Pseudomonas aeruginosa, and Vibrio cholera form. Poly β-(1→6)-N-acetyl-
D-glucosamine (PNAG) is a major component of biofilms and has been found to play 
a key role in the early stages of the biofilm life-cycle. However, little information is 
known about what proteins interact with this important polysaccharide. Our goal is to 
create small PNAG analogues to covalently capture and identify PNAG binding 
partners in E. coli, an important model organism. PNAG analogues will contain 
photoaffinity groups, that when activated, covalently link associated proteins to the 
probe. Using a proteomics-mass spectrometry-based approach, PNAG binding 
partners will be identified. We describe the efforts and challenges encountered 
  
synthesizing the final PNAG probes. New synthetic routes are proposed based on 
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Bacterial biofilms consist of communities of bacteria that are attached to a 
surface1, and pose a major concern in the medical industry. There is an increasing 
prevalence of antibiotic-resistant infections, including those by methicillin resistant 
Staphylococcus aureus (MRSA), which result from highly virulent biofilm-forming 
bacterial strains2,3. Other bacteria also form biofilms, including Escherichia coli, 
Pseudomonas aeruginosa, and Vibrio cholera, and the formation of biofilm 
contributes to their associated diseases (urinary tract infection, cystic fibrosis 
complications, and cholera, respectively).3,4 Despite the problems caused by biofilms 
in our society, the factors that regulate their formation are not well understood. 
Understanding how biofilms grow and mature could lead to the discovery of new 
treatments to combat their inherent drug resistance, or to modulate biofilm formation 
to better serve our purposes.  
 
Figure 1: Life cycle of biofilms. (1) Initial cell attachment; (2) cell division and EPS 
secretion, irreversible attachment, (3) multi-layered cell clusters, early biofilm stage, 
(4) mature biofilm, (5) planktonic cell release and colonization.5 
 
The biofilm life-cycle has five stages beginning with planktonic bacterial 
cells. First,  a single planktonic bacterium attaches itself transiently to a surface 





on the surface accompanied by a transition to permanent surface attachment (Figure 
1-2), which is key for further biofilm development for most bacteria.5 Also, at this 
stage, the bacteria begin to secrete an extracellular polymeric substance (EPS) 
(Figure 2) composed of extracellular DNA (eDNA), proteins, lipids, and exo-
polysaccharides.6 The colony is classified as a biofilm at the third stage (Figure 1-3), 
and is characterized by multi-layered cell clusters.5 The fourth stage involves biofilm 
maturation to form complex three dimensional cell networks imbedded within the 
EPS and offers the best protection against antibiotics (Figure 1-4).5 The final stage 
involves the release of planktonic bacterial cells from the mature biofilm to colonize a 
new surface (Figure 1-5).5  While the general steps of the biofilm life-cycle are well 
established, there is still relatively little known about the specific interactions in the 
EPS that regulate each step of biofilm formation and structure.   
 
Figure 2: The major components of the EPS are extracellular DNA (eDNA), 






Understanding the structure and function of the EPS is a target of current 
research due to its secretion in the early stages of biofilm formation and as a result of 
its critical functions supporting biofilms. These include providing mechanical 
structure to the biofilm, aiding in metabolism, and protecting cells from the outside 
environment. 3,4,6 The EPS aids to anchor cells of the biofilm to a surface mainly 
through exopolysaccharide secretion and eDNA, depending on the species.6,7 
Additionally, the EPS contributes to the often highly ordered structure of the biofilm, 
by facilitating cell–cell attachment and increasing cell density, which gives the 
biofilm stability.6,8,9,10,11,12  The EPS aids in cellular metabolism by sequestering 
enzymes that digest outside components as well as the EPS itself, including exo-
polysaccharides, which is important to release planktonic bacteria in the later stages 
of the biofilm life cycle. 1,6,13 The EPS is responsible for protecting the biofilm from 
the outside environment through a variety of mechanisms. First, the EPS also retains 
water, which is essential to keep the biofilms hydrated in dry environments.6 Also, the 
eDNA present in the EPS is used to transfer genetic information between bacteria, 
conferring greater antibiotic resistance to the biofilm as a whole.6 Lastly, the EPS acts 
as a physical barrier between the biofilm and the outside environment analogous to 
skin.6 The exo-polysaccharide component of the EPS is known to slow diffusion of 
antibiotics and harmful toxins.6,3  
Exo-polysaccharide components of the biofilm EPS play an important role in 
maintaining biofilm structure and cell-surface attachment, which are key factors in 
biofilm growth and development. For example, in V. cholera, vibrio polysaccharide 





protein RmbA to facilitate proper cell–cell attachment and maintain the proper 
architecture of the biofilm.8,14 Mutants lacking RmbA produced biofilms that are 
larger but more susceptible to mechanical disruption due to the lack of cell–cell 
connections.14 The RmbA–VPS interaction is one of the first protein/exo-
polysaccharide interaction to be observed and suggest an important role of exo-
polysaccharides in maintain cell–cell contact through protein–carbohydrate binding 
interaction during biofilm development.  
In addition to VPS, the exo-polysaccharide,  poly β-1,6-N-acetyl-D-
glucoseamine (PNAG) (Figure 3) is an important adhesion factor in several bacterial 
species and was first discovered first in S. epidermidis in 1999.15 Since the discovery 
of PNAG, there have been key studies over the past 20 years that further support its 
importance in other species of bacteria. For example, in 2005, PNAG was discovered 
to be important for the organization of E. coli strain K12 cells.16 This was done by 
creating a mutant that lacked the necessary glycotransferase PgaC, which is 
responsible for PNAG export, and determining the difference in attachment patters 
compared to the wild type.16 Mutant and wild type cells were allowed to grow on a 
slide for 4 hours, then the slide was inverted and the number of cells on the slide were 
counted at 10 min intervals for 1 hour.16 Additionally, fast Fourier transform spectra 
were taken at the start of the growth assay and at 20 min and 60 min.16 Based upon 
fast Fourier transform analysis, pgaC mutants showed no defined structure after 60 
min, as compared to the wild-type.16 The further disorganization of the pgaC 
mutants cells was confirmed by microscopy, as the cells were mainly attached to the 





The lack of cell–cell connections was seen by the gravity displacement assay 
described above as the cell density of the pgaC mutant decreased over the course of 
60 min and the cells were not able to form a 3-D biofilm.16 These observations 
indicated that PNAG may be an important adhesion factor for the K12 strain as well 
as an important factor in maintaining the structure of the cells during biofilm 
maturation.16  
 
Figure 3: General structure of PNAG. On average, 10-20% of residues are 
deacetylated.  
 
In addition to E. coli, PNAG is also found in other human pathogens and is an 
important adhesion factor in gram-negative bacteria such as V. cholera14 and 
Acinetobacter baumanii17, as well as gram-positive bacteria S. aureus18 and 
Staphylococcus epidermidis19, which commonly infect medical devices. For all of 
these species, biofilm is a major virulence factor in animal infection models20 and 
blocking cell-EPS interactions is a potential strategy for the development of drugs to 
inhibit biofilm development. Recently, progress has been made in understanding the 
proteins that control PNAG synthesis and export. In 2018, a study was published 
describing how the manipulation of PNAG synthesis and transportation proteins can 





is encoded by the pgaABCD operon along with other proteins that control PNAG 
synthesis and export in E. coli.22 PgaB is a two-domain periplasmic protein which 
contains a N-terminal carbohydrate esterase domain as well as a C-terminal PNAG 
binding domain which facilitates PNAG export from the cell.21  The C-terminal 
domains for both E. coli and Bordetella bronchiseptica were able to hydrolyze 
deacetylated PNAG (dPNAG) from S. aureus, and were shown to disrupt PNAG 
dependent biofilms of Bordetella pertussis, Staphylococcus carnosus, S. epidermidis, 
and E. coli.21 Additionally, it was determined that the PgaB domains of both species 
hydrolyzed dPNAG with a GlcN-GlcNAc-GlcNAc motif at the reducing end of the 
new fragment, indicating that the deacetylation state of PNAG is important for 
cleavage and export.21 Overall, this work indicates strongly that PNAG is an integral 
part of the biofilm, as the hydrolysis of PNAG by the C-terminal domain of B. 
bronchiseptica and E. coli PgaB was able to disrupt biofilms that utilize PNAG in 
multiple species. 
Research Plan: 
 It is clear that PNAG plays a critical role in the structure and development of 
bacterial biofilms, but exactly how it contributes to biofilm development at a 
molecular level remains elusive. To that end, the goal of this project is to identify 
and characterize PNAG binding protiens using a targeted proteomics approach. 
This will lead to a better understanding of the mechanisms by which PNAG 
functions in biofilm growth and development in E. coli, an important model 
organism. Protein–carbohydrate binding interactions are frequently hard to capture 





of μM to mM).23 Therefore, to capture these low affinity binding interactions we plan 
to use a photoaffinity-labeling based strategy to covalently cross-link the PNAG 
probe to the target protein, allowing for analysis of the protein using mass-
spectrometry based approaches.24,25 For our approach, a diazirine functional group 
was selected as the photoactivatable cross-linking group for several reasons. 
Diazirines are a photo-active protein crosslinking functional group that forms a highly 
reactive carbene when exposed to UV light around 365 nm (Figure 4). This carbene 
then can insert itself into O-H, C-H, S-H, and N-H bonds of proteins that are in close 
proximity to the carbene, forming a permanent covalent linkage. Since the diazirine is 
indiscriminate in terms of where it inserts, we should be able to capture most protein-
PNAG associations with this probe. Another benefit to using diazirines over other 
photoactive groups, such as aryl azides and benzophenones, is that diazirines are 
more reactive and less bulky, and are therefore less likely to interfere with normal 
binding interactions between the probe and target proteins.  
Figure 4: Mechanism of diazirine degradation and insertion into O-H, C-H, S-H, or 
N-H bonds.  
 
We will incorporate the diazirine onto short segments of synthetic PNAG 





paper published in 2009 by Nitz and coworkers that described a synthesis of PNAG 
probes using HFpyridine to synthesize short polymers of N-acetyl-D-glucosamine to 
the desired length of our probes.26 After the initial PNAG probe is constructed, we 
will attach the diazirine moiety to our PNAG using two different methods (Scheme 
1).  
We chose to explore two different methods to link a diazirine reactive group 
to our PNAG oligosacharides (Scheme 1). First, in the type I probe the diazirine, 
which is derived from levulinic acid using literature methods27,28, is attached to a free 
primary amine of GlcN residues present in the PNAG as the NHS ester (compound 
4). A potential downside of this approach is that the diazirine will be incorporated at 
variable positions along the PNAG polymer chain, leading to a heterogeneous 
mixture, which may affect protein binding and capture. Additionally, the modified 
levulinc acid could interfere with protein active sites and important PNAG-protein 
interactions may not be captured effectively. As an alternative, the type II probe 
incorporates the diazirine on a bifunctional linker (compound 5) via the anomeric 
position, eliminating the variability.26,29 The main difficulties with this strategy are 
the complex route to the synthesis of compound 5 and the coupling of compound 5 












Scheme 1: Type I and Type II probes that will be used to conduct binding 
experiments with E. coli cell lysate. Each probe type incorporates the diazirine at 
different positions in the PNAG backbone.  
 
Once both probes are synthesized, we then plan incubate the probes with cell 
lysate derived from cultures of E. coli biofilms (Figure 5). Then, we will activate the 
diazirine with UV light, which will cross-link the PNAG probe to any interacting 
proteins. The probe and cross-linked proteins will be isolated and enriched through 
streptavidin affinity purification using streptavidin coated magnetic beads and washed 
to eliminate any proteins that are not covalently cross-linked. Proteins attached to the 
probe will be digested with trypsin and the free amines on the peptide will be 
methylated using sodium cyanoborohydride and formaldehyde and versions with 























































































the two controls.30 From there, we can see if any characterized proteins interact with 
PNAG and potentially study these proteins in the future. 
Figure 5: Approach to isolate and characterize PNAG binding partners using a 
targeted-proteomics approach. A PNAG probe without the photoaffinity ligand and a 
chitosan probe including the photoaffinity ligand will act as negative controls.   
 
A common problem associated with targeted-proteomics based approaches is 
differentiating between non-specific and specific binding interactions captured with 
the affinity probes. Our approach will incorporate two controls to account for non-
specific interactions: one using a synthetic PNAG probe lacking the diazirine moiety 
and the other employing chitosan as the backbone for the probe (Figure 5). Chitosan 
is composed of glucosamine linked through β-(1→4) glycosidic bonds instead of the 
β-(1→6) linkages found in PNAG. This difference in the glyosidic linkage leads to 
structural differences between chitosan and PNAG in solution where chitosan adopts 
a linear conformation and PNAG forms a helical structure.31 Based upon the different 
architectures of the polysaccharides in solution, the chitosan probe should be an ideal 
negative control for our targeted-proteomics approach. The synthesis of chitosan 





design. Using these controls should allow for differentiation between specific PNAG 
binding proteins and those that simply bind non-specifically to GlcNAc and GlcN.  
This type of proteomics-based approach using diazirines as the main 
photoactive group have been well documented in the literature. First, a study that was 
attempting to understand the mechanism of action of fatty acid esters of 
monogalactosyldiacylglycerol (MGDG), used the diazirine as a crosslinker to 
determine what proteins bind to it.32 MGDG’s have anti-tumor, anti-viral, and anti-
inflammatory properties, which make them attractive drug targets.33 The modified 
MGDG with the diazirine was incubated in cell lysate and bound proteins were 
isolated and run on an SDS-page gel, stained with silver, and the most intense bands 
were sent for LC/MS-MS analysis.32 Toll-like-receptor 4 was identified to be the 
major protein that bound to the probe and later it was determined that MGDG is an 
inhibitor of TLR4, which explains the anti-inflammatory effects of MGDG’s.32 Also, 
diazirines have been used to identify proteins that bind to pseudomonas quinoline 
signal (PDS), a virulence factor in the QS pathway of P. aeruginosa.34 A modified 
PDS with a diazirine was incubated with cell lysate and enzymes were captured that 
interacted with the modified probe.34 Captured proteins included lipopolysaccharide 
biosynthesis enzymes and proteins essential for virulence.34 Overall, these studies 
indicate the power of diazrine crosslinkers and proteomics techniques involving 
carbohydrates and bacteria.  
In this thesis I describe our synthesis and characterization of PNAG 





of the bifunctional linker. Work is still underway to establish an optimal methodology 
to link both diazirine containing compounds to the PNAG oligosaccharides.  
Preliminary Results and Discussion:  
Synthesis of PNAG and chitosan: 
 We started the synthesis of both PNAG probes by employing an acid 
reversion process to form the N-acetylglucosamine polymer 6 (Scheme 2). This 
process has been previously described26, and is a protecting group-free method to 
prepare PNAG derivatives more efficiently than other chemical approaches, such as 
various one-pot synthesis35, solid phase synthesis36,37, or convergent approaches37,38, 
and can provide more material than direct isolation of PNAG from E. coli cell 
cultures. We carried out the acid reversion process by dissolving N-
acetylglucosamine in 70% HF-pyridine for up to a week, two days longer than the 
published procedure of 5 days.26 A greater yield of the n>5 polymer was observed 
when the solution was stirred for 7 days as compared to 5 days. Also, the higher 
molecular weight (n>5) fraction after 7 days contained n = 8–12 oligosaccharides that 
were not observed after 5 days. Size exclusion chromatography on a bio-gel P6 
column was used to separate the reaction products into three fractions based on their 
molecular weight. A high molecular weight fraction (n>5, 18%), a medium weight 
fraction (n=3-5, 40%) and a low molecular weight fraction (n < 3 37%) were 
isolated. However, we were unable to purify the products down to a single length 
size. In the future, additional size exclusion chromatography steps are likely required 





While the synthesis of compound 6 proved successful, the deacetylation of 6 
to give compound 3 proved a challenge (Scheme 2). In E. coli, roughly 20% of the 
monosaccharides in PNAG are deacetylated39, and we wanted our probes to mimic 
native PNAG as much as possible. Initially, we attempted the saponification of 6 in 
10M NaOH, a strategy employed previously by others26,40. However, after many 
attempts, this approach proved unsuccessful. We hypothesized that the free anomeric 
hydroxyl group was interfering with the deacetylation, as hydroxide could be 
attacking this position over the acetyl groups. Lending further support to our theory, 
in the work by Nitz, the anomeric position was protected by using an O-alkyl-N-
methyl hydroxylamine derived linker, which prevented any side reaction of NaOH.26 
Thus, we attempted to use N,O-dimethyl hydroxylamine to protect the reducing-end 
GlcNAc 41, of compound 6 to generate compound 7 (Scheme 3). Once the anomeric 
protecting group was  
Scheme 2: Initial synthetic plan for type I probes. The chitosan probe lacks the 
deacetylation step. 
 
70% HF in pyridine
1 week

































































































installed, the PNAG oligomer could be deacetylated using the same basic conditions 
to form compound 8, then deprotected to give compound 3.41 However, attachment of 
the protecting group proved unsuccessful, possibly due to the poor solubility of 
PNAG under the conditions needed to solubilize the protecting group. After the failed 







Scheme 3: First attempt to work around the PNAG deacetylation problem. 
 Our new strategy to make PNAG involved replacing N-acetylglucosamine in 
the first step, with a N-phthalimide-protected glucosamine 9 (Scheme 4).42 The 
protected glucosamine 9, will be employed as the monomer in the acid reversion 
reaction to make N-phthalimide-protected poly-glucosamine 10. The phthalimide 
protecting group will be removed using hydrazine hydrate, a common method to 
remove phthalate protecting groups, to give compound 11.  Currently, the first step in 
this new method has proven successful, as compound 9 was isolated by reacting 
glucosamine HCl with phthalic anhydride in a sodium bicarbonate solution (38%). 
The next two steps in the process should go smoothly as well, and the removal of the 





The synthesis of the chitosan-derived negative control probes started with 
commercially available high molecular weight chitosan. A number of methods to 
make low molecular weight chitosan oligosaccharide fragment (n=5–8) from high 
molecular weight chitosan (~ 50,000-190,000 Da) were attempted, including 
sonication44, molecular sieve facilitated hydrolysis45, and finally treating with 
concentrated HCl,46 which proved to be the most effective method. High molecular 
weight chitosan was dissolved in concentrated aqueous HCl and heated to ~70oC for 
1.5 hrs, and the reaction was quenched by adding 10 M NaOH until the pH reached 7. 
However, the main challenge with this synthesis was the removal of the salts 
generated after the reaction was quenched. Most of the salts were removed by 
removing as much of the aqueous solution as possible by rotary evaporation, which 
caused salts to crash out of solution. Then the concentrated solution containing the 
desired fragments was decanted to separate the salts. More salts were removed on the 
FPLC when purifying the fragments further. However, after various attempts to 
remove the salts, there were some present in the fractions collected after FPLC.  
Scheme 4: Revised synthesis of PNAG to circumvent issues with deacetylation. This 
process removes the deacetylation step all together and relies on a N- deprotection 






Synthesis of type I probe with PNAG and chitosan: 
The synthesis of the type I probe for PNAG and chitosan started with the 
synthesis compound 4 (Scheme 1). The synthesis was carried out by dissolving 
levulinic acid in 7M NH3 in methanol, along with hydroxylamine-O-sulfonic acid, 
followed by iodine titration to yield compound 12 (52%) (Scheme 2)27. This is more 
technically simple than using than liquid NH3
29, which can also be employed to make 
the diazirine functional group. Using NH3 in methanol did not affect the yield of 
compound 12, as the yield obtained was in line with what is reported in the literature. 
With compound 12 in hand, we attempted to react it with purified chitosan oligomers 
using an EDC amide coupling using a sub stoichiometric ratio of compound 12 
relative to the chitosan oligomers to attach on average a single 12 per chitosan 
oligomer to give the chitosan analogue of compound 13 (Scheme 2).27 We chose to 
employ an EDC coupling as the amide is formed in one step and reacts selectively 
with the free amine, ignoring the unprotected hydroxyl groups of the chitosan/PNAG 
oligosaccharide. However, after a few attempts, this coupling was unsuccessful, 
mainly due to the poor solubility of chitosan in methanol/water. We were unable to 
attempt the EDC coupling with PNAG as we were unable to deacetylate our 
synthesized PNAG (compound 6) as described previously. 
To circumvent the solubility issues, we decided to implement an amide 
coupling strategy that is known to work well with chitosan in aqueous conditions and 
should be applicable to PNAG as well (Scheme 5). This strategy involves forming a 
N-hydroxysuccinimide ester from compound 12 to make compound 4 using a 





conditions with compound 11 to form an amide with the free amine (compound 13a, 
Scheme 5)47. Once the amide bond is formed, the next steps in the synthesis can be 
carried out, including acetylation and biotinylation to form the completed chitosan 




Scheme 5: Synthesis of the N-hydroxysuccinimide ester of compound 12 to form 
compound 13a. 
 
Synthesis of type II probe with PNAG and chitosan: 
 We chose to use 1-hydroxyhept-6-yn-3-one (compound 17) as a starting 
material to synthesize the bifunctional linker (compound 5, Scheme 1) as it has the 
required functional groups necessary for creating our probe (Scheme 6). Compound 
17 contains a primary hydroxyl group that can be further functionalized, a terminal 
alkyne that can be used for copper-catalyzed click reactions, and central ketone 
equally spaced between the other two functional groups, which can be converted into 
a diazirine. 
 We initially purchased compound 17 to use in the synthesis of the final 
linker; however, due to its high cost (over $100 a gram) and limited availability from 
common chemical manufacturers we also sought to synthesize 17 in house. 
Compound 17 could be readily prepared using established literature methods 
(Scheme 6).49 First, ethyl acetoacetate is allowed to react with two equivalents of 
HO
O




































LDA followed by the addition of propargyl bromide to form compound 14.49 Then, 
the ketone is protected as the ketal using ethylene glycol to give compound 15. The 
ester of 15 is then reduced with LiAlH4 to generate the primary alcohol 16.
49 The 
ketal is then removed under acidic conditions to yield compound 17.49 So far, only the 
first step to form compound 16 in 30% yield has been completed. The yield was low 
but may be improved  following a new literature protocol from 2019, which obtained 






Scheme 6: Synthesis of 1-hydroxyhept-6-yn-3-one, the starting bifunctional linker for 
strategy 2. 
 
Our initial strategy to prepare the type II probe began by synthesizing the 
bifunctional linker (compound 5, Scheme 7) by forming the Boc-protected 
hydroxylamine (compound 20) from a tosylate-primed intermediate (compound 18).26 
Then, the diazirine would be formed (compound 21) using a similar approach used to 
form the diazirine on levulinic acid,27 and the hydroxylamine would be deprotected 
using TFA to yield compound 5.26 Out of this initial plan, the only step that was 
successful was the formation of compound 18, which was isolated in a 64% yield, in 
line with the literature.51 The reaction of compound 18 with synthesized Boc-
protected N-methyl hydroxylamine (compound 19, 69%)52 to generate the Boc-
























the failure of this strategy could be that the hydride was deprotonating the alpha 
carbons on either side of the ketone or the terminal hydrogen on the alkyne, as the 








Scheme 7: Retrosynthetic analysis of the original strategy to achieve the bifunctional 
linker that will react with PNAG and chitosan. 
 
In an attempt to circumvent this problem, we proposed a new synthetic route 
to prepare 20 using a Mitsunobu reaction (Scheme 8). After attempting the reaction at 
room temperature without success, we found that reacting compound 17 and 19 with 
PPh3 and DIAD at 45
oC, gave compound 20 in a moderate yield (40%).53 This 
approach also required on fewer steps than our previous route by directly conjugating 
compound 17 and 19 instead of making the intermediate 18. Compound 20 was then 
treated following the previously described method to form the diazirine 21. While 
formation of the diazirine proved successful, the hydroxylamine was lost during the 
reaction. We therefore decided to first convert the ketone of 17 to the diazirine to give 
22 in 31% yield, followed by the Mitsunobu reaction with compound 19 to yield 21 
in 41% yield (Scheme 9). The Boc group was then successfully removed using TFA 
to form compound 5 (27%). Next, the conjugation of compound 5 with compound 11 
to make the thermodynamically stable β-glycoside (compound 23) was attempted 


























solubilities of the bifunctional linker and PNAG are not compatible in aqueous 
conditions. Second, and more likely, is that the equilibrium constants of the reaction 
between the anomeric position and the N-methyl hydroxylamine is low, and 1,4-
diaminobenzene may need to be employed as a catalyst to speed up the reaction.53,54 
The final steps in the synthesis to make the type II probes for PNAG (compound 2) 
and chitosan will be acetylation of the free amines by using acetic anhydride in excess 
followed by the copper-catalyzed click reaction with the terminal alkyne of the linker 
and azide-PEG3-Biotin.
48 Overall, we predict that our revised synthesis will lead to 













Scheme 9: Current strategy to couple the bifunctional linker 5 to PNAG and chitosan 









11, 6:1 H2O/AcOH, DMF
60oC, 24h N
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Conclusions and Future Directions: 
 The main challenges with the synthesis of the type I and type II PNAG and 
chitosan probes was the deacetylation of PNAG and the coupling of both diazirine 
probes. To solve the PNAG deacetylation problem, a new synthesis was outlined 
where the free amine of glucosamine was protected with phthalic anhydride to create 
the new monomer 9 to be used in the acid-reversion reaction to produce the PNAG 
backbone (compound 10). The phthalaminde protecting group can then be easily 
removed so that all amines in the PNAG background are free to accept compound 4 
to generate compound 13. This type of amide coupling to form the type I probes is 
commonly used and is known to work well with chitosan and should be adapted 
relatively easily to PNAG.  
 The synthesis of the bifunctional linker used in the type II probe was more 
challenging as the starting bi-functional linker 17 had to be synthesized. After 
troubleshooting problems coupling the N-Boc-N-methyl hydroxylamine 19 to 
compound 17, we settled on using a mitsunobu reaction. The final challenge with 
synthesizing the type II probes will be conjugating the bifunctional linker 22 with the 
anomeric position of PNAG or chitosan. Recent literature suggests that this reaction 
can be accelerated with the use of a 1,4-diaminobenzene catalyst.  
 The proposed enhancements to the synthesis of the type I and type II probes 
should be relatively straightforward as most of the proposed changes have literature 
precedent. An estimated time frame to synthesize the type I and type II PNAG and 
chitosan probes would be 2 months. Two weeks would be needed to produce enough 





synthesis of 4 and 17. Finally, two weeks would be needed to complete the 
conjugation of compounds 4 or 17 with 11 and chitosan oligomers and the final two 
weeks would be used as a buffer in case any issues arose with the previously outlined 
steps. Following completion of the synthesis, the protein capture experiments using E. 
coli lysate and the characterization of any PNAG binding proteins is expected to take 
another 2 months, for an estimated completion of the project in 4 months. Any PNAG 
binding proteins identified using this approach will be investigated in greater detail to 
establish their function in PNAG dependent biofilm formation. If we are able to 
identify and then block specific PNAG binding proteins this may provide a new 
avenue to disrupt and prevent biofilm growth. Additionally, we can utilize our probes 
in other species of biofilm-forming bacteria that use PNAG in their EPS to see if 









Compounds were used as received from Sigma Aldrich without modification. All 
solvents used were Sure-Seal solvents unless otherwise noted. TLC was performed on 
silica at ambient temperature. Silica gel 60 was used as the stationary phase for flash 
chromatography. All 1H NMR spectra were taken using a Bruker Advance 400 MHz 
Fourier Transform Nuclear Magnetic Resonance Spectrometer. Abbreviations for 
spectra: s = singlet, br = broad singlet d = doublet, t = triplet, q = quartet, quin = 








Poly-(1→6)-β-N-acetyl-D-glucosamine (PNAG) (6). N-Acetyl-D-glucosamine (2.00 
g, 9.04 mmol) was added to a polypropylene conical tube, followed by 1.40 mL of 
HF (~70% in 30% pyridine, Sigma Aldrich). The contents were stirred for 7 to 14 
days and were subsequently quenched through the addition of a slurry of calcium 
carbonate (6.00 g) in ice until the evolution of gas ceased (~30 min). The suspension 
was poured over celite and washed with water which yielded a pale yellow filtrate. 
The filtrate was concentrated in vacuo and filtered through 3 separate C18 silica 
columns (5.0 cm x 2.5 cm). Filtrate from the C18 columns were concentrated again in 
vacuo and injected onto a Bio-Gel P4 size exclusion column (5.0 cm I.D. x 70 cm, 
40-90 µm particle size). MilliQ water was used as the eluent at 0.5 mL/min and 
column progress was monitored at 215 nm. Fractions with similar elution times were 
combined, concentrated in vacuo  to give 6 as an off white solid (122 mg, n ≥ 5; 18% 
yield). The product distribution was characterized using MALDI-TOF MS using 
THAP as the matrix. m/z (MALDI) major peaks: 1056.23 n=5; 1259.34 n=6; 1462.42 










yl)isoindoline-1,3-dione (9). A solution of D-glucoseamine HCl (5.39 g, 25.0 mmol), 
phthalic anhydride (3.70 g, 25.0 mmol), and sodium bicarbonate (4.20 g, 50.0 mmol) 





pH 2 with 2 M HCl, which after 5 min, caused a white suspension to form. The 
precipitate was washed with water and dried using a Buchner funnel to yield the 
desired compound as a white solid. (2.95 g, 38%) δH (400 MHz; CDCl3) 7.97-7.95 
(dd, 1H, J=1.0, 7.5 Hz), 7.68-7.58 (m, 2H), 7.54-7.51 (dd, 1H, J=1.0, 7.5 Hz), 5.34 
(d, 1H, J=3.5 Hz), 4.09-4.04 (dd, 1H, J=3.5 ,10.6 Hz), 3.91-3.76 (m, 4H), 3.53 (t, 1H, 












Chitosan Oligomer Production. Chitosan (2.00 g) was placed in a 1-neck round 
bottom flask along with a stir bar. Next, 100 mL of neat HCl poured into the flask and 
the flask was submerged in an oil bath at 68.5oC for 1.5 hrs with the top open to allow 
HCl to vent into the fume hood. After heating, the cloudy brown solution inside the 
flask was quenched by placing it in a dry-ice acetone bath for 10 min. The pH was 
adjusted to 3-4 with 10 M NaOH while the flask was in the dry ice/acetone bath to 
prevent overheating. During addition of NaOH, a precipitate could be seen forming. 
Next, activated charcoal was added and the solution was filtered through a Millipore, 
22 µm filter using a Buchner funnel. The resulting clear-yellow filtrate was 
concentrated to ~50 mL in vacuo. Once condensed, the solution was brought to pH 8-
9 and turned from clear-yellow to clear-brown and the solution was filtered through 2 
C18 columns (5.0 cm x 2.5 cm) and re-concentrated in vacuo. A 6 mL aliquot was 
placed on the size exclusion column Bio-Gel P4 size exclusion column (5.0 cm I.D. x 
70 cm, 40-90 µm particle size) using MilliQ water as the eluent at 0.5 mL/min while 
monitored for absorbance at 215 nm. MALDI:1049.22 n=6, 1210.27 n=7, 1371.31 








4,4-azo-pentanoic acid (12). A round bottom flask was charged with a stir bar and 
capped with a septum that had a syringe with a balloon attached. Next, levulinic acid 
(700 µL, 6.80 mmol) was injected into the flask and the flask was submerged in an 





Aldrich, 47.6 mmol) was added and the solution was stirred in the ice bath for 3 hrs. 
Hydroxylamine O-sulfonic acid (885 mg, 7.82 mmol) in 7 mL MeOH was then added 
dropwise. The reaction was kept stirring while slowly warming to r.t. in the ice bath 
for 18 hrs. Ammonia was removed from the solution by gently blowing air over the 
solution for 1 hr. The white precipitate that had formed was removed by pouring the 
mixture over Celite and the precipitate was washed several times with cold MeOH, 
leaving a pale yellow filtrate. The filtrate was concentrated in vacuo, covered with 
aluminum foil, and submerged in an ice bath for 5 min.  Next, 1.50 mL of TEA (10.3 
mmol) was added and the flask sat in the ice bath for 5 min while the mixture was 
stirred. Then, making sure to limit exposure to light, iodine chips were slowly added 
to the mixture until the solution remained a persistent dark brown (about 1 g of 
iodine) and the solution was stirred in the ice bath for an hour. The mixture was 
poured into a separatory funnel followed by 10 mL of EtOAc and 10 mL 1 M HCl to 
wash the organic layer. The aqueous layer was extracted with 3x20 mL of EtOAc. 
The organic layers were combined and washed with 3x15 mL of sodium thiosulfate 
hexahydrate and 30 mL brine then dried over Na2SO4. The solvent was removed by 
rotary evaporation resulting in a yellow-orange oil and stored at -20oC (0.460 g, 
52%). δH (400 MHz; CDCl3) 9.81 (br, 1.5H), 2.16 (t, 2H, J=8 Hz), 1.63 (t, 2H, J=8 








succinimidyl 4,4-azipentanoate (4). Compound 12 (0.350 g, 2.70 mmol), N-
hydroxysuccinimide (0.34, 2.97 mmol), and EDC hydrochloride (0.570 g, 2.97 mmol) 
were dissolved in 10 mL anhydrous methylene chloride at 0oC. The solution was then 
stirred at room temperature for 2 h and the solution had turned to olive green. The 
solution was then diluted with 10 ml of methylene chloride and washed 3x25 mL of 
dH2O and 1x25 mL brine. The organic layer was dried over MgSO4 and concentrated 
by rotary evaporation to yield an orange solid. δH (400 MHz; CDCl3) 2.87 (s, 4H), 








ethyl 3-oxohept-6-ynoate (14). A solution of 2 M LDA in THF and hexanes (Sigma-
Aldrich) (12.7 mL, 25.4 mmol) was added to a pre-chilled round bottom flask 
equipped with a stir bar. Next, ethyl acetoacetate (16.2 mL, 12.68 mmol) was added 
and upon addition, a violent reaction and off-gassing could be seen taking place. The 





red. The solution was stirred for 30 min, then propargyl bromide (9.61 ml, 12.68 
mmol) was added and the solution was stirred for an additional hour in the ice bath. 
The addition of the propargyl bromide turned the solution from a dark red to a clear 
vivid-orange and some bubbling was also observed. After 1 h, the reaction was 
quenched with glacial acetic acid (14.5 mL, 25.36 mmol) which caused a precipitate 
to form. Equal portions of DI H2O and diethyl ether (75 mL) were added to the 
organic layer. The aqueous layer was separated from the organic layer and extracted 
with 50 mL diethyl ether. The organic layers were combined and washed with 50 mL 
of brine and dried over sodium sulfate. Excess solvent was removed in vacuo and the 
dark orange oil that was left was stored at 0oC until further use. Optimal column 
conditions (90% hexanes, 10% ethyl acetate, vanillin stain, Rf = 0.28) were 
determined by TLC. The crude oil was placed on a 30 g silica column from Biotage 
and run on a Biotage automated column using the above TLC conditions. The column 
progress was monitored by UV vis (200-400 nm) and appropriate fractions were 
combined and condensed using rotary evaporation to yield a yellow oil (600 mg, 
28%). δH (400 MHz; CDCl3): 4.12 (q, 2H, J = 6.5 Hz), 3.90 (d, 2H, J = 9.2 Hz), 2.75 
(t, 1H, J = 7.2 Hz), 2.39 (t, 1H, J = 6.5 Hz), 2.19 (s, 1H), 1.91 (t, 1H, J = 19.2 Hz), 









3-oxohept-6-yn-1-yl 4-methylbenzenesulfonate (18). A round bottom flask was 
charged with a stir bar and purged with argon followed by the addition of 1-
hydroxyhept-6-yn-3-one (200 mg, 1.59 mmol), 4-toluenesulfonyl chloride (465 mg, 
2.38 mmol), pyridine (385 L, 4.76 mmol), and 5 mL of dry methylene chloride. The 
mixture was placed in an ice bath and left to stir for 20 h under argon. Next, the 
mixture was poured into a separatory funnel along with 10 mL DI H2O. The aqueous 
layer was extracted with 10 mL of methylene chloride and the combined organic 
layers were dried over Na2SO4 and residual solvent was removed in vacuo. The 
optimal TLC conditions to give an Rf = 0.37 were 70% hexanes, 30% ethyl acetate. 
The yellow oil obtained was placed on a Biotage silica gel column and run on a 
Biotage automated column chromatography system. Fractions containing the product 
were combined and solvent removed using rotary evaporation to give a yellow oil 
(286 mg, 64%). δH (400 MHz; CDCl3) 7.78 (d, 2H, J = 8 Hz), 7.36 (d, 2H, J = 8 Hz), 
4.28 (t, 2H, J = 6 Hz), 2.83 (t, 2H, J = 6 Hz), 2.65 (t, 2H, J = 7.2 Hz), 2.44 (m, 5H), 












tert-butyl methyl((3-oxohept-6-yn-1-yl)oxy)carbamate (19). A round bottom flask 
was charged with a stir bar and purged with argon for 10 min. Next, N-methyl 
hydroxylamine (927 mg, 11.1 mmol) and di-tertbutyl decarbonate (1940 mg, 8.88 
mmol) were added to the flask and dissolved in approx 32 mL of dry methylene 
chloride. Triethylamine was then added (1.95 mL, 13.8 mmol) and the reaction was 
stirred for 18 h under argon atmosphere. After stirring overnight, the clear, colorless 
solution was washed with 0.1 M Na2SO4 (3x30 mL) followed by brine (2x30 mL). 
The organic layer was dried with sodium sulfate and the solid was removed by 
gravity filtration. The excess organic solvent was removed in vacuo to give a clear, 
magenta oil. A proton NMR was taken of the oil in CDCl3. (897 mg, 69%). δH (400 









tert-butyl methyl((3-oxohept-6-yn-1-yl)oxy)carbamate (20). A round bottom flask 
was charged with a stir bar along with triphenylphosphine (375 mg, 1.43 mmol). The 
flask was capped with a septum and purged with argon for 10 min. Then, 4 mL of dry 
THF was added to the flask and the resulting solution was stirred for 5 min. Next, 
compound 17 (120 L, 0.95 mmol) was added, followed by compound 19 (260 L, 
1.90 mmol). The flask was submerged in an ice bath for 1 min, then DIAD (350 L, 
1.76 mmol) was added dropwise. The flask was then removed from the ice bath and 
was allowed to warm to RT for 10 min while stirring. Once warmed to RT, the flask 
was submerged in an 50oC oil bath for 18 hrs. After heating, excess solvent was in 
vacuo, resulting in an oily yellow residue. The residue was dissolved in 
dichloromethane and a TLC was taken in 30% ethyl acetate, 70% hexanes and stained 
with ninhydrin, which showed that the product had a Rf = ~0.55. The residue was run 
on a Biotage silica gel column on a Biotage automated column system with the 
respective TLC plate settings. Appropriate fractions were isolated and condensed using 
rotary evaporation. Proton NMR in CDCl3 showed that unreacted compound 8 was still 
present after chromatography. The residue was then dissolved in 15 mL of diethyl ether 
and washed with 20 wt% sodium bisulfate solution (3x10 mL), 0.1 M NaOH (2x10 
mL), and brine (1x10 mL. The organic layer was further dried using sodium sulfate and 
excess solvent was removed by rotary evaporation. A proton NMR of the oil was taken 
in CDCl3 (243 mg, 41%). δH (400 MHz; CDCl3) 4.1 (t, 2H, J=6 Hz), 3.03 (s, 3H), 2.70 















2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethan-1-ol (23). Compound 17 (250 mg, 1.98 
mmol) was added to a round bottom flask equipped with a stir bar. The flask was sealed 
with a septum and placed in an ice-water bath for 5 min. A balloon was attached to the 
septum to maintain pressure within the flask. Next, 7M ammonium hydroxide in 
methanol (1.98 mL, 13.87 mmol) was injected into the flask and the flask was left in 
the ice bath for 3 hrs with stirring. A solution of hydroxylamine-O-sulfonic acid (258 
mg, 2.28 mmol) in a minimal amount of methanol was then injected dropwise and the 
resulting solution was stirred for 18 h while it warmed to RT. After stirring overnight, 
a white suspension had formed in the flask. The precipitate was separated from the 
pale-yellow solution by syringe filter and the precipitate was washed with cold 
methanol. The solution was concentrated in vacuo, leaving a yellow oil residue. The 
residue was then dissolved in 2 mL methanol and transferred to a round bottom flask 
covered in aluminum foil and placed in an ice bath for 5 min while stirring. 
Triethylamine (420 µL, 3.01 mmol) was added and the flask was stirred in the ice bath 
for another 5 min. A solution of iodine (654 mg, 2.57 mmol) in a minimal amount of 
methanol was added dropwise until the color of the solution was persistently purple. 
The flask was kept in the ice bath for an additional hour while stirring. Afterwards, the 
reaction was diluted in 10 mL ethyl ether, followed by washing with 10 mL brine. The 
brine was washed with diethyl ether (3x10 mL) and the combined organic layers were 
dried with sodium sulfate. Excess solvent was removed in vacuo, resulting in a yellow 
oil. The oil was run on a Biotage silica gel column that was used with a Biotage 
automated column system with 80% hexanes, 20% ethyl acetate. Appropriate fractions 
(Rf = 0.25, plate stained with vanillin) were collected, combined, and condensed in 
vacuo to yield a pale yellow oil (90 mg, 33%). δH (400 MHz; CDCl3): 3.46 (t, 2H, J = 









tert-butyl (2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethoxy)(methyl)carbamate (21). 
Compound 23 (90.0 mg, 0.71 mmol) was combined with triphenylphosphine (281 
mg, 1.07 mmol) in a round bottom flask equipped with a stir bar. The flask was then 





turned on. Next, Compound 19 (210 mg, 1.43 mmol, 2 eq) was added when the first 
two reagents had dissolved and the flask was placed in an ice bath for 5 min to cool. 
DIAD (267 mg, 1.32 mmol) was added dropwise and the flask was taken out of the 
ice bath after the addition was complete. The flask was then placed in an oil bath set 
at 45OC overnight. A TLC was then taken of the crude in 70% hexanes and 30% ethyl 
acetate which gave an Rf = 0.68 for the target compound when stained with vanillin 
and ninhydrin. Next, 10 mL of diethyl ether was added to the organic layer and 
washed with 20 wt% potassium bicarbonate (10 x 3 mL) followed by 0.1 M sodium 
hydroxide (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over 
sodium sulfate and the organic layer was condensed in vacuo, resulting in a yellow 
oil. TLC was performed with similar conditions as above on the yellow oil to confirm 
the removal of excess compound 9. The crude oil was run through a Biotage silica gel 
column on a Biotage automated column system with the same TLC conditions used 
for this compound previously. Similar fractions were combined and condensed via 
rotary evaporation to yield a pale yellow oil (61 mg, 32%). δH (400 MHz; CDCl3): 
3.77 (t, 1H, J = 6 Hz), 3.67 (t, 1H, J = 6 Hz), 3.09 (d, 3H, J = 6 Hz), 2.04-1.95 (m, 









Compound 21 (60.0 mg, 0.22 mmol) was placed into a round bottom flask covered 
with aluminum foil and charged with a stir bar. Next, 0.33 mL (0.68 M) of TFA in 
dichloromethane (1:3) was added to the linker - the color of the solution became 
darker and bubbling was observed. The solution was stirred at RT for 30 min then 10 
mL of diethyl ether was added to the flask. The organic layer was washed with 
saturated sodium bicarbonate (3x10 mL), dried over sodium sulfate, and filtered by 
gravity filtration. The organic solvents were removed by rotary evaporation to give a 
yellow oil. A 1H NMR confirmed that the product had been formed but was impure 
(10 mg, 15%). δH (400 MHz; CDCl3): 3.60 (t, 2H, J = 6.4 Hz), 2.048-1.981 (m, 6H), 
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